CGON
Price
$26.22
Change
-$0.34 (-1.28%)
Updated
May 21 closing price
Capitalization
2B
77 days until earnings call
NUVL
Price
$73.66
Change
-$2.22 (-2.93%)
Updated
May 21 closing price
Capitalization
5.29B
77 days until earnings call
Interact to see
Advertisement

CGON vs NUVL

Header iconCGON vs NUVL Comparison
Open Charts CGON vs NUVLBanner chart's image
CG Oncology
Price$26.22
Change-$0.34 (-1.28%)
Volume$1.22M
Capitalization2B
Nuvalent
Price$73.66
Change-$2.22 (-2.93%)
Volume$423.31K
Capitalization5.29B
CGON vs NUVL Comparison Chart
Loading...
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGON vs. NUVL commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGON is a StrongBuy and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (CGON: $26.22 vs. NUVL: $73.66)
Brand notoriety: CGON and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGON: 75% vs. NUVL: 70%
Market capitalization -- CGON: $2B vs. NUVL: $5.29B
CGON [@Biotechnology] is valued at $2B. NUVL’s [@Biotechnology] market capitalization is $5.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGON’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • CGON’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, CGON is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGON’s TA Score shows that 5 TA indicator(s) are bullish while NUVL’s TA Score has 7 bullish TA indicator(s).

  • CGON’s TA Score: 5 bullish, 5 bearish.
  • NUVL’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than CGON.

Price Growth

CGON (@Biotechnology) experienced а +8.48% price change this week, while NUVL (@Biotechnology) price change was +3.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.17%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was -1.67%.

Reported Earning Dates

CGON is expected to report earnings on Aug 07, 2025.

NUVL is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.29B) has a higher market cap than CGON($2B). NUVL YTD gains are higher at: -5.902 vs. CGON (-8.577). CGON has higher annual earnings (EBITDA): -95.94M vs. NUVL (-322.59M). NUVL has more cash in the bank: 1.07B vs. CGON (541M). CGON has higher revenues than NUVL: CGON (684K) vs NUVL (0).
CGONNUVLCGON / NUVL
Capitalization2B5.29B38%
EBITDA-95.94M-322.59M30%
Gain YTD-8.577-5.902145%
P/E RatioN/AN/A-
Revenue684K0-
Total Cash541M1.07B50%
Total Debt296KN/A-
TECHNICAL ANALYSIS
Technical Analysis
CGONNUVL
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
72%
Bullish Trend 23 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
50%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KSMIX9.22N/A
N/A
Keeley Small-Mid Cap Value I
MPSSX19.59N/A
N/A
BNY Mellon Small Cap Multi-Strategy M
AMDVX15.95N/A
N/A
American Century Mid Cap Value R6
BVALX14.45N/A
N/A
Brown Advisory BeutelGoodmanLg-CpValInst
EQNCX21.37-0.43
-1.97%
MFS Equity Income C

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
-1.28%
IDYA - CGON
57%
Loosely correlated
-2.45%
ACLX - CGON
57%
Loosely correlated
+8.26%
SYRE - CGON
56%
Loosely correlated
-4.03%
RCKT - CGON
56%
Loosely correlated
-3.80%
KYMR - CGON
56%
Loosely correlated
-4.17%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with CGON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-2.93%
CGON - NUVL
53%
Loosely correlated
-1.28%
ABCZF - NUVL
51%
Loosely correlated
N/A
KYMR - NUVL
51%
Loosely correlated
-4.17%
CRNX - NUVL
48%
Loosely correlated
-4.53%
RVMD - NUVL
48%
Loosely correlated
-4.27%
More